# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
-Reuters
Moderna wins a crucial legal battle at the European Patent Office against Pfizer and BioNTech over Covid-19 vaccine patents.
https://www.ft.com/content/50c5078c-c9f0-4b35-b916-3475b641c773Moderna has won a case at the European Patent Office in its disp...
Evercore ISI Group analyst Cory Kasimov initiates coverage on BioNTech (NASDAQ:BNTX) with a In-Line rating and announces Pri...
Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists.
HC Wainwright & Co. analyst Robert Burns maintains BioNTech (NASDAQ:BNTX) with a Buy and raises the price target from $1...
TD Cowen analyst Yaron Werber maintains BioNTech (NASDAQ:BNTX) with a Hold and raises the price target from $95 to $98.